Dtsch Med Wochenschr 2008; 133(44): 2289-2291
DOI: 10.1055/s-0028-1091275
Kommentar | Commentary
© Georg Thieme Verlag KG Stuttgart · New York

Arzneimitteltherapie im Alter: Zu viel und zu wenig, was tun?

Ein neues Bewertungssystem: fit for the aged (FORTA)Drug therapy in the elderly: too much or too little, what to do?A new assessment system: fit for the aged (FORTA)M. Wehling1
  • 1Klinische Pharmakologie Mannheim, Universität Heidelberg
Further Information

Publication History

eingereicht: 13.5.2008

akzeptiert: m21.8.2008

Publication Date:
22 October 2008 (online)


  • 1 Beckett N S, Peters R, Fletcher A E. et al . Treatment of hypertension in patients 80 years of age or older.  N Engl J Med. 2008;  358 1887-1898
  • 2 Beers M H. Explicit criteria for determining potentially inappropriate medication use by the elderly.  Arch Intern Med. 1997;  157 1531-1536
  • 3 Black D M, Brand R J, Greenlick M, Hughes G, Smith J. Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program.  J Gerontol. 1987;  42 552-557
  • 4 Borchelt M. Potential side-effects and interactions in multiple medication in elderly patients: methodology and results of the Berlin Study of Aging.  Z Gerontol Geriatr. 1995;  28 420-428
  • 5 Dahlöf B, Devereux R B, Kjeldsen S E. et al . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.  Lancet. 2002;  359 (9311) 995-1003
  • 6 Düsing R. Adverse events, compliance, and changes in therapy.  Curr Hypertens Rep. 2001;  3 488-492
  • 7 Fick D M, Cooper J W, Wade W E, Waller J L, Maclean J R, Beers M H. Updating the Beers Criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.  Arch Intern Med. 2003;  163 2716-2722
  • 8 Field T S, Gurwitz J H, Harrold L R. et al . Risk factors for adverse drug events among older adults in the ambulatory setting.  J Am Geriatr Soc. 2004;  52 1349-1354
  • 9 Field T S, Mazor K M, Briesacher B, Debellis K R, Gurwitz J H. Adverse drug events resulting from patient errors in older adults.  J Am Geriatr Soc. 2007;  55 271-276
  • 10 Hasford J, Schröder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study.  Eur J Clin Pharmacol. 2007;  63 1055-1061
  • 11 Hense H W. MONICA Study: Epidemiology of arterial hypertension and implications for its prevention. 10-yeart results of the MONICA Study Augsburg.  Dtsch Med Wochenschr. 2000;  125 1397-1402
  • 12 Kaufman D W, Kelly J P, Rosenberg L, Anderson T E, Mitchell A A. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey.  JAMA. 2002;  287 337-344
  • 13 Lazarou J, Pomeranz B H, Corey P N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.  JAMA. 1998;  279 1200-1205
  • 14 Lin H Y, Liao C C, Cheng S H, Wang P C, Hsueh Y S. Association of potentially inappropriate medication use with adverse outcomes in ambulatory elderly patients with chronic diseases: experience in a Taiwanese medical setting.  Drugs Aging. 2008;  25 49-59
  • 15 Linden M, Bär T, Helmchen H. Prevalence and appropriateness of psychotropic drug use in old age: results from the Berlin Aging Study (BASE).  Int Psychogeriatr. 2004;  16 461-480
  • 16 Page 2nd  R L, Ruscin J M. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use.  Am J Geriatr Pharmacother. 2006;  4 297-305
  • 17 Pugh M J, Hanlon J T, Zeber J E, Bierman A, Cornell J, Berlowitz D R. Assessing potentially inappropriate prescribing in the elderly Veterans Affairs population using the HEDIS 2006 quality measure.  J Manag Care Pharm. 2006;  12 537-545
  • 18 Pugh M J, Rosen A K, Montez-Rath M. et al . Potentially inappropriate prescribing for the elderly: effects of geriatric care at the patient and health care system level.  Med Care. 2008;  46 167-173
  • 19 Robine J M, Michel J P. Looking forward to a general theory on population aging.  J Gerontol A Biol Sci Med Sci. 2004;  59 M590-597
  • 20 Schnurrer J U, Frölich J C. Zur Häufigkeit und Vermeidbarkeit von tödlichen unerwünschten Arzneimittelwirkungen.  Internist (Berl). 2003;  44 889-895
  • 21 Schönhöfer P S. Klinik-basierte Erfassung Arzneimittel-bedingter Erkrankungen im Pharmakovigilanz-System (ZKH Bremen).  Arzneimitteltherapie. 1999;  17 83-86
  • 22 Shepherd J, Blauw G J, Murphy M B. et al . PROSPER study group.. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.  Lancet. 2002;  360 1623-1630
  • 23 Staessen J A, Fagard R, Thijs L. et al . Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.  Lancet. 1997;  350 757-764
  • 24 Steinman M A, Landefeld C S, Rosenthal G E, Berthental D, Sen S, Kaboli P J. Polypharmacy and prescribing quality in older people.  J Am Geriatr Soc. 2006;  54 1516-1523
  • 25 Van den Akker M, Buntinx F, Metsemakers J F, Roos S, Knottnerus J A. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases.  J Clin Epidemiol. 1998;  51 367-375
  • 26 Van Spall H G, Toren A, Kiss A, Fowler R A. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review.  JAMA. 2007;  297 1233-1240
  • 27 Zhan C, Sangl J, Bierman A S. et al . Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey.  JAMA. 2001;  286 2823-2829

Prof. Dr. Martin Wehling

Klinische Pharmakologie Mannheim, Universität Heidelberg

Maybachstraße 14

68169 Mannheim

Phone: ++49 621 383 9631

Fax: ++49 621 383 9632

Email: martin.wehling@medma.uni-heidelberg.de